Atreca, Inc.
835 Industrial Road
Suite 400
San Carlos, CA 94070
United States
650 595 2595
https://www.atreca.com
版塊: Healthcare
行業: Biotechnology
全職員工: 90
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. John A. Orwin M.B.A. | President, CEO, Director & Principal Financial Officer | 927.03k | 無 | 1965 |
| Dr. Tito A. Serafini Ph.D. | Founder & Director | 665.5k | 無 | 1963 |
| Mr. Rick Ruiz | Principal Accounting Officer | 無 | 無 | 1964 |
| Ms. Courtney J. Phillips J.D. | General Counsel & Corporate Secretary | 無 | 無 | 1975 |
| Roger Richard Ruiz | Vice President of Finance | 無 | 無 | 無 |
描述
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.
公司管治
截至 2024年5月1日 止，Atreca, Inc. 的 ISS 管治質素評分為 10。 Pillar 分數正在審核中：8；董事會：8；股東權利：10；現金賠償：10。
